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Abstract
Background: An inverse relation between Helicobacter py-
lori infection and asthma has been shown in epidemiological 
studies. Infection with H. pylori, or application of an extract 
of it before or after sensitization, inhibits allergic airway dis-
ease in mice. Objectives: The aim of this study was to inves-
tigate the effect of an extract of H. pylori on allergic airway 
disease induced by repeated allergen exposure in mice that 
were sensitized and challenged prior to extract application. 
Method: C57BL/6 mice were intranasally (i.n.) sensitized and 
challenged with house dust mite (HDM). After a minimum of 
4 weeks, mice received the H. pylori extract intraperitoneally 
and were rechallenged i.n. with HDM. Allergen-specific anti-
bodies were measured by ELISA. Cells present in the bron-
choalveolar lavage fluid and dendritic cell (DC) subsets in the 
lung tissue were analyzed by flow cytometry. Tissue inflam-
mation and goblet cell hyperplasia were assessed by histol-
ogy. Cells of the mediastinal lymph node (mLN) were isolat-
ed and in vitro restimulated with HDM or H. pylori extract. 
Results: Treatment with H. pylori extract before rechallenge 
reduced allergen-specific IgE, the DC numbers in the tissue, 
and goblet cell hyperplasia. Cells isolated from mLN of mice 
treated with the extract produced significantly more IL-10 
and IL-17 after in vitro restimulation with HDM. mLN cells of 
H. pylori-treated mice that were re-exposed to the H. pylori 
extract produced significantly more interferon gamma. Con-
clusions: An extract of H. pylori is effective in reducing mucus 
production and various features of inflammation in HDM re-
challenged mice. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Asthma is a common syndrome of increasing preva-
lence [1]. Current treatment of patients with asthma con-
sists of anti-inflammatory drugs such as inhaled cortico-
steroids, often in combination with bronchodilators. All 
available treatment options are symptomatic, and symp-
toms usually return when treatment is paused or stopped. 
Also, disease-modifying effects by novel treatments with 
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monoclonal antibodies against IgE [2, 3] or IL-5 [4] in 
patients with severe asthma have not been shown. Fur-
thermore, 5–10% of patients do not respond to high-dose 
therapies (a combination of high-dose inhaled/oral corti-
costeroids and β2-adrenoceptor agonists) [5] and the 
number of novel drugs for asthma that have reached the 
market is small considering the efforts made and costs ac-
crued [6]. Therefore, further efforts are needed to develop 
treatments that modify the course of the disease. 
Colonization of the stomach with the bacterium H. py-
lori has been shown to protect against the development of 
asthma in many epidemiological studies [7, 8]. Experi-
mental infection with Helicobacter pylori or treatment 
with an H. pylori extract before sensitization to allergens 
inhibited allergic airway inflammation (AAI) in murine 
models [9–11]. Protection was dependent on the induc-
tion of tolerogenic dendritic cells (DCs). We recently 
showed that AAI was also reduced when the extract was 
applied at a later point of induction of AAI, i.e., in mice 
that had been sensitized (but not yet challenged) prior to 
treatment with the H. pylori extract [12]. Antigen pro-
cessing by DCs was reduced in vivo and in vitro after ex-
posure to the extract. 
However, the model of acute airway disease that we 
have investigated so far has the drawback that treatment 
is administered before airway inflammation has devel-
oped. In patients with allergic asthma, symptoms and air-
way inflammation repeatedly occur after allergen expo-
sure [1]. Therefore, we set out to test a potential treatment 
in a model with repeated allergen exposures to assess the 
potential therapeutic effect. 
We hypothesized that an extract of H. pylori would re-
duce allergic airway disease induced by repeated allergen 
exposure when applied to mice that were previously sen-
sitized and challenged. To this end, mice were sensitized 
and challenged prior to a period of rest, treated with the 
extract, and then rechallenged with the allergen. 
Materials and Methods
Animals
Eight- to twelve-week-old female C57BL/6 mice were purchased 
from Charles River (‘s-Hertogenbosch, The Netherlands). The ani-
mals had free access to food and water, and were housed in individ-
ually ventilated cages under specific pathogen-free conditions. Ex-
periments were performed at the animal facilities of the Leiden Uni-
versity Medical Center in Leiden, The Netherlands. The Ethics 
Committee for Animal Experimentation of the University of Leiden 
approved the experiments (Dieren Experimentele Commissie, DEC, 
12246), which were conducted under strict governmental and inter-
national guidelines in accordance with EU Directive 2010/63/EU.
Experimental Protocols for AAI Induced by Rechallenge and 
Intervention
To induce AAI, mice were intranasally (i.n.) sensitized with 
1 μg of house dust mite (HDM; Greer, Lenoir, NC, USA) in 50 μL 
of PBS, and challenged by five i.n. applications of 10 μg HDM in 
50 μL of PBS 1 week later (Fig. 1). After a period of rest of at least 
4 weeks, the mice were rechallenged by three i.n. applications of 10 
μg HDM in 50 μL of PBS. As a control, some mice that were sen-
sitized and challenged with HDM received PBS at the time that the 
other mice were rechallenged with HDM. All i.n. administrations 
were performed under isoflurane anesthesia (3%, 0.8 L/min). H. 
pylori extract (200 μg) in 100 μL of PBS was applied intraperitone-
ally (i.p.) 5 and 3 days before the rechallenge and was continued 
daily from 1 day before the rechallenge to 1 day thereafter. As a 
control, the remaining mice received 100 μL of PBS i.p. On days in 
which the mice were both treated with the extract and were rechal-
lenged with HDM, the extract was administered 1 h before HDM 
exposure. Mice were analyzed 2 days after the final HDM expo-
sure. Mice were euthanized with an overdose of sodium pentobar-
bital (Euthasol, AST Farma, Oudewater, The Netherlands). Analy-
ses of the blood, bronchoalveolar lavage (BAL) fluid, and lung tis-
sue were performed as previously published [12]. Blood was 
collected from the vena cava. After three lavages of the lungs with 
1 mL of PBS that was applied via a tracheal canula, the lungs were 
perfused with PBS via the heart. The mediastinal lymph node 
(mLN) was removed and collected in PBS. For flow cytometry 
analysis, the left lobe of the lungs was collected in PBS. To study 
the histology, the right lobes were inflated with 3.9% (v/v) formal-
dehyde (Sigma-Aldrich) in PBS after ligature. 
Preparation of H. pylori Extract
The H. pylori extract was prepared as previously published [12]. 
In short, the H. pylori pre-mouse SS1 strain (PMSS1) was cultured 
on solid agar plates (bioMérieux Benelux B.V., Zaltbommel, The 
Netherlands) under microaerophilic conditions (6% O2, 7.1% 
CO2, 7.1% H2, and 79.7% N2; Anoxomat, Mart Microbiology, 
Drachten, The Netherlands). After testing of the production of a 
specific combination of enzymes to assure that the culture con-
tained H. pylori, the bacteria were transferred to BBL broth with 
10% FCS (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, 
USA) and were further cultured under microaerophilic conditions 
at 37  ° C in a shaking incubator (New Brunswick Scientific Europe 
B.V., Nijmegen, The Netherlands) at 185 rpm. After checking the 
purity by Gram-staining of the pellets, the bacteria were pooled, 
washed in PBS, freeze-thawed in nitrogen, and subjected to a pres-
sure of 3,000 bar in a French pressure cell press (Stansted Fluid 
Power, Cell Pressure Homogenizer, Harlow, UK). The superna-
tant was filtered through a 0.2-µm filter and the protein content 
was determined using bicinchoninic acid (BCA protein Kit Pierce, 
Thermo Fisher Scientific). The concentration of the extract was 
adjusted using PBS.
Anti-HDM IgE and IgG1
Serum was obtained by centrifugation of the collected blood, 
and was diluted in 1% (w/v) BSA/PBS (Sigma-Aldrich). NUNC 
Maxisorb plates (Sigma-Aldrich) were coated with 50 µg/mL of 
HDM in 0.1 M sodium-carbonate buffer pH 9.6 and non-specific 
binding sites were blocked with 1% BSA/PBS. After incubation 
with the samples, HDM-specific antibodies were detected using 
biotin-labelled anti-mouse IgE (clone 23G3; Southern Biotech, 
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Birmingham, AL, USA) or biotin-labelled anti-mouse IgG1 (clone 
A85-1; BD Pharmingen, Becton Dickinson B.V., Breda, The Neth-
erlands). Streptavidin coupled to HRP (Sanquin, Amsterdam, The 
Netherlands) and TMB (3,3′,5,5′-tetramethylbenzidine) were add-
ed to quantify the antibody binding. A Bio-Rad iMark microplate 
reader was used for measurement of the ODs at 450 nm.
Flow Cytometry
Quantification of cells in the BAL fluid was performed using 
Türk’s solution (Merck, Schiphol-Rijk, The Netherlands). A single 
cell suspension was obtained from lung tissue by dissecting the tis-
sue into small pieces. Collagenase/DNAse (Collagenase Type I 
of Clostridium histolyticum; Calbiochem, San Diego, CA, USA; 
DNAse I; Sigma-Aldrich) was added for 45 min at 37  ° C. The mix-
ture was filtered through a 70-µm cell strainer (BD Falcon, Becton 
Dickinson). After the lysis of red blood cells, the cells were count-
ed on a Countess automatic cell counter (Invitrogen, Thermo Fish-
er Scientific). The mLN was filtered through a 70-µm cell strainer 
(BD Falcon, Becton Dickinson) and the single cell suspension was 
counted using trypan blue. Cells of the BAL fluid, lung tissue, and 
mLN were labelled with the live/dead stain Aqua (Invitrogen, 
Thermo Fisher Scientific). Cells of the BAL fluid and lung tissue 
were fixed with 2% formaldehyde (Merck) in PBS. The antibodies 
used for flow cytometry and gating strategies for analysis have been 
previously published [12]. Treg analysis of cells in the mLN was 
performed using the eBioscience Foxp3/Transcription factor 
staining buffer set (Invitrogen). The following antibodies were 
used: CD4-FITC (GK1.5, eBioscience, Thermo Fisher Scientific), 
CD25-PerCP-Cy5.5 (PC61, BD Pharmingen, Becton Dickinson 
B.V.), FOXP3-APC (FJK-16s, eBioscience, Thermo Fisher Scien-
tific), CD3-eFl450 (17A2, eBioscience, Thermo Fisher Scientific). 
Antibody mixes were supplemented with mouse FcγRII/III-bind-
ing inhibitor (2.4G2, Bioceros, Utrecht, The Netherlands). A 
FACSCanto II (BD Bioscience, Becton Dickinson B.V.) and FlowJo 
(v7.6.5) software (Tree Star, Ashland, OR, USA) were used for data 
acquisition and analysis. Gates were placed according to unstained 
and Fluorescence Minus One samples; the gating strategy for the 
Tregs can be found in online Supplementary Figure 1 (for all online 
suppl. material, see www.karger.com/doi/10.1159/000500598).
Histology
Paraffin sections of 4 μm were obtained from formaldehyde-
inflated tissue (fixed for 48 h at room temperature). Peribronchial 
inflammation was scored on a 5-point scale (0–4) after staining 
with hematoxylin and eosin (HE, both Klinipath, Duiven, The 
Netherlands). In this semiquantitative method, 0 indicates that no 
inflammation around airways or vessels was detected; 1 indicates 
that there were some infiltrates of maximum two layers thick; 2 
indicates that infiltrates of up to two layers were found at the ma-
jority of airways and vessels, and occasionally thicker layers were 
found; 3 indicates that the majority of airways and vessels were 
inflamed with more than two layers of cells, but occasionally thin-
ner layers were present; and 4 indicates that all airways and vessels 
were surrounded by thick layers of inflammatory cells. The analy-
sis was performed by two separate investigators in a blinded fash-
ion. Goblet cell hyperplasia was assessed in tissue stained with Al-
cian blue and periodic acid-Schiff (PAS) dyes (both from Sigma-
Aldrich). Digital images were taken at 10× magnification on an 
Olympus BX41 microscope (Olympus Nederland B.V., Leider-
dorp, The Netherlands). Epithelial regions were selected and the 
fraction of positively stained area corresponding to mucin density 
was calculated using ImageJ software 1.46r (National Institute of 
Health, Bethesda, MD, USA). 
Treatment Analysis
Group
PBS
HDM
Treatment (i.p.)
PBS
PBS
H. pylori extractHDM H.p.
Group Sensitization
(i.n.)
PBS
HDM
HDM
HDM
HDMHDM H.p.
Group
PBS
HDM
Challenge
(i.n.)
HDM
HDM
HDMHDM H.p.
Rechallenge
(i.n.)
PBS
HDM
HDM
Group
PBS
HDM
HDM H.p.
Week 1 Week 2 Week 6 or 18
1–3.5 months rest
Fig. 1. Experimental setup of the rechallenge model of AAI. 
C57BL/6 mice were sensitized by i.n. application of HDM, and 
challenged i.n. with HDM on days 7–11. After 1–3.5 months of 
rest, the mice were rechallenged with HDM i.n. An extract of H. 
pylori was administered i.p. 5 and 3 days before the rechallenge, 
and daily from 1 day before the rechallenge until 1 day after. The 
extract was administered 1 h before HDM exposure on the days of 
the rechallenge. Analyses were performed 2 days after the final 
HDM exposure. H.p., H. pylori.
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Cytometric Bead Array
The mLN was removed from mice that underwent H. pylori or 
control treatment for AAI. The mLN was mashed through a 70-µm 
falcon cell strainer and the strainer was washed with Dulbecco’s PBS 
(Gibco, Thermo Fisher Scientific). After centrifugation, 200,000 
cells were cultured in 10% FCS RPMI supplemented with 100 U/mL 
penicillin and 100 U/mL streptomycin (Lonza), and stimulated with 
(10 µg/mL) HMD or (10 µg/mL) H. pylori extract for 4 days. Super-
natant was collected and subjected to cytometric bead array (BD 
Biosciences) according to the manufacturer’s protocol.
Statistical Analysis
GraphPad PRISM 7.02 (GraphPad Software Inc., La Jolla, CA, 
USA) was used to create graphs and to perform statistical analysis. 
Data are shown as means ± standard error of the mean (SEM). Dif-
ferences were considered significantly different at p values < 0.05 
examined by ANOVA and the Dunnett multiple comparisons 
analysis. For analysis of cytokine production after stimulation of 
mLN, the two-stage step-up method of Benjamini, Krieger, and 
Yekutieli was applied to correct for multiple comparisons when 
performing multiple t tests.
Results
Mice were initially sensitized with HDM in week 1 and 
then challenged during week 2. Following a rest period of 
at least 4 weeks, the mice were rechallenged with HDM. 
The mice were i.p. treated with an extract of H. pylori 
prior to a rechallenge (see the experimental set up Fig. 1). 
HDM-specific IgE was significantly induced following re-
challenge with HDM compared to exposure to PBS 
(Fig. 2a). Treatment with H. pylori extract resulted in a 
significant reduction of anti-HDM IgE levels in serum. 
However, mice that were rechallenged and treated with 
the H. pylori extract did have significantly higher anti-
HDM IgE levels compared to mice that received PBS at 
the moment of rechallenge (p = 0.001). No difference in 
HDM-specific IgG1 levels could be detected between 
mice rechallenged with HDM compared to mice that re-
ceived PBS at the rechallenge, and HDM-specific IgG1 
was not affected by the treatment (Fig. 2b). 
Control mice that received PBS only instead of HDM 
at rechallenge exhibited low total cell counts and low 
numbers of eosinophils in BAL fluid, showing that in-
flammation induced by the first challenge of sensitized 
mice was mostly resolved after the period of rest (Fig. 3a, 
b). Rechallenge with HDM led to a significant increase in 
the number of total cells in the BAL fluid, which was not 
affected by treatment with H. pylori extract. When assess-
ing differential cell counts in BAL fluid, relative and ab-
solute numbers of eosinophils in the BAL fluid were in-
creased following rechallenge with HDM (Fig.  3b, c). 
Treatment with H. pylori extract resulted only in a small, 
but significant, reduction in the percentage of eosinophils 
(Fig. 3c). Absolute numbers of eosinophils in BAL fluid 
were not statistically significantly reduced (Fig. 3b).
In the lung tissue, inflammation was low following i.n. 
exposure to PBS at the time when other mice were rechal-
lenged with HDM (Fig.  4a, b) as only few infiltrates 
around the airways and blood vessels of the lung were 
found. Rechallenge with HDM resulted in a significant 
increase in inflammation as assessed by HE staining of the 
lung tissue. Overall inflammation of the lung tissue was 
not inhibited by treatment with the extract. No mucus 
production was detected in mice after rechallenge with 
PBS (Fig. 4a, c), but HDM rechallenge resulted in an in-
crease in mucus production. Mice treated with H. pylori 
extract showed a significant reduction in mucus produc-
tion. We have reported previously that treatment with the 
H. pylori extract between sensitization and challenge led 
to a reduction in the number of DCs in the lung, a shift in 
the subtypes of DCs, and a reduced capacity to process 
antigen [12]. In the therapeutic model, the number of 
DCs in the lungs was also reduced, however we did not 
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Fig. 2. HDM-specific antibodies in serum. 
a Anti-HDM IgE. b Anti-HDM IgG1. PBS, 
sensitized and challenged with HDM, re-
challenged with PBS; HDM, sensitized and 
challenged with HDM, rechallenged with 
HDM; HDM H.p., sensitized and chal-
lenged with HDM, treated with H. pylori 
extract, rechallenged with HDM. Results 
are presented as the mean ± SEM of two 
experiments, n = 13–15 per group. Groups 
were compared by ANOVA with Dun-
nett’s multiple comparison correction. ns, 
non-significant. * p ≤ 0.05; **** p ≤ 0.0001.
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detect a shift in the ratio of CD11b+ proinflammatory to 
CD103+ anti-inflammatory DCs, or in the ratio of pro-
inflammatory monocyte-derived CD11b+CD64+ DCs to 
conventional CD11b+CD64– DCs (Fig. 5).
The mLN is the lymph node that drains the lungs, and 
it was shown to also be involved in drainage after i.p. in-
jection of ovalbumin in alum [13]. Therefore, we were 
interested in mLN responses to the allergen and the ex-
tract. When cells of the mLN were restimulated with 
HDM, the cells of mice that were in vivo treated with H. 
pylori extract prior to the rechallenge produced signifi-
cantly more IL-10 and IL-17 than cells of mice rechal-
lenged with HDM without being treated with the extract 
(Fig. 6a). After in vitro restimulation with H. pylori ex-
tract, cells of mice that were in vivo treated with the ex-
tract produced more interferon gamma (IFNγ) than cells 
of mice that did not receive the extract in vivo. The per-
centage of Foxp3+ Tregs in the mLN was decreased after 
treatment of the mice with H. pylori extract (Fig. 6b).
Discussion
Previous studies have shown that the induction of AAI 
is reduced in mice infected with H. pylori or treated with 
an H. pylori extract prior to the induction of allergy [9–11]. 
Also, the application of an extract of the bacterium after 
sensitization results in amelioration of the development of 
the disease [12]. In the present study, we investigated a pos-
sible therapeutic effect of treatment directly before a re-
challenge in previously sensitized and challenged animals. 
The results show that intervention at rechallenge leads to 
a reduction of select, but not all features of the disease. In-
deed, HDM-specific IgE in serum was significantly re-
duced in mice treated with the H. pylori extract. In the lung 
tissue, the number of DCs and extent of goblet cell hyper-
plasia were significantly reduced. Cells from the mLN of 
mice treated with the H. pylori extract that were restimu-
lated with HDM produced significantly more IL-10 than 
mLN cells of mice that were not treated with the extract.
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Fig. 3. Analysis of the BAL fluid after treatment of AAI induced by 
HDM rechallenge with an extract of H. pylori. a Exact amount of 
cells present in the BAL fluid quantified by counting in Türk’s so-
lution. b Number of eosinophilic granulocytes present in the BAL 
fluid. The total amount of cells in the BAL fluid was multiplied by 
the percentage of eosinophils determined by flow cytometry. c Dif-
ferential of the BAL fluid, as determined by flow cytometric analy-
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HDM, treated with H. pylori extract, rechallenged with HDM. Re-
sults are presented as the mean ± SEM of two experiments, n = 
13–16 per group. Groups were compared by ANOVA with Dun-
nett’s multiple comparison correction. ns, non-significant. ** p ≤ 
0.01; **** p ≤ 0.0001.
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sessed by flow cytometry. PBS, sensitized and challenged with 
HDM, rechallenged with PBS; HDM, sensitized and challenged 
with HDM, rechallenged with HDM; HDM H.p., sensitized and 
challenged with HDM, treated with H. pylori extract, rechallenged 
with HDM. Results are presented as the mean ± SEM of two ex-
periments, n = 10–15 per group. Groups were compared by ANO-
VA with Dunnett’s multiple comparison correction. ns, non-sig-
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with HDM; HDM H.p., sensitized and challenged with HDM, 
treated with H. pylori extract, rechallenged with HDM. Results are 
presented as the mean ± SEM of two (b) or one (c) experiment(s), 
n = 15–16 (b) or n = 6–8 (c) per group. Groups were compared by 
ANOVA with Dunnett’s multiple comparison correction. ns, non-
significant. *** p ≤ 0.001; **** p ≤ 0.0001.
Effect of H. pylori Extract on Allergen 
Rechallenge
7Int Arch Allergy Immunol
DOI: 10.1159/000500598
To mimic asthma in vivo, we used a rechallenge mod-
el of AAI. This is a relevant model, as patients with aller-
gic asthma can show increased inflammation and symp-
toms following allergen exposure, but can also be asymp-
tomatic. Still, the residual inflammation in patients that 
do not experience any symptoms can contribute to a next 
attack. It was previously shown that inflammation was 
mostly resolved 6 weeks after sensitization and challenge 
of mice with OVA, but that a secondary challenge alone 
induced inflammation in these mice [14], indicating that 
prior allergic airway disease contributes to the develop-
ment of AAI after a second challenge.
Whereas most attempts to inhibit AAI with micro-or-
ganism-based approaches have been described in preven-
tive models, some studies [12, 15] showed that AAI can 
be inhibited when micro-organism preparations are ap-
plied to sensitized mice. Fewer studies report on success-
fully inhibiting AAI when applying micro-organism 
preparations after a prior sensitization and challenge [15, 
16]. Thorburn et al. [15] showed that components of 
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Fig. 6. Effects of in vivo H. pylori extract treatment on the mLN. 
a Cytokine production by cells from the mLN of H. pylori extract-
treated mice. Mice were treated with the extract and rechallenged 
with HDM. The mLN was removed and restimulated with medi-
um, HDM, or H. pylori extract (10 µg/mL) for 4 days. Quantifica-
tion of IL-5, IL-10, IL-13, IL-17, and IFNγ by cytometric bead ar-
ray. b Treg in the mLN of mice after H. pylori extract treatment of 
AAI induced by HDM rechallenge. HDM, sensitized and chal-
lenged with HDM, rechallenged with HDM; HDM H.p., sensitized 
and challenged with HDM, treated with H. pylori extract, rechal-
lenged with HDM. Cytokine results are presented as the mean ± 
SEM of two experiments, n = 9–16 per group. Cytokine production 
was analyzed by the two-stage step-up method of Benjamini, 
Krieger, and Yekutieli (multiple t tests, corrected for multiple com-
parisons). p values are shown only for comparisons where the 
 statistical method showed a discovery. ns, non-significant; re-
stim., restimulation. ** p ≤ 0.01; **** p ≤ 0.0001. Treg results are 
presented as the mean ± SEM of one experiment, n = 8 per group. ** p ≤ 0.01.
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Streptococcus pneumoniae applied during established dis-
ease inhibited allergic airway disease by the induction of 
Tregs that inhibited natural killer T-cells. Lagranderie et 
al. [16] demonstrated inhibition of AAI by a freeze-dried 
preparation of Mycobacterium bovis BCG applied after 
the induction of established disease, which was associated 
with the induction of the immunosuppressive cytokine 
IL-10. The persistence of the observed treatment effects 
requires further analysis. Navarro et al. [17] showed that 
a mix of bacterial extracts (Broncho-Vaxom, used for re-
current respiratory infections) could inhibit AAI when 
applied orally from 1 day before the sensitization until the 
challenge. When mice were rechallenged 3 weeks later, 
treatment was no longer effective, indicating that protec-
tion was short lived. Others showed that treatment that 
was started before the sensitization was still effective 
when mice were challenged 30 days after infection with 
Escherichia coli [18]. 
In our experience, treatment at a later stage of the dis-
ease (before a second challenge) affected goblet cell hy-
perplasia, but had less effect on inflammation compared 
to treatment before the first challenge [12]. To reduce in-
flammation caused by a rechallenge, more frequent injec-
tions with H. pylori extract for a longer period of time 
might be required. 
The largest effect of treatment was on goblet cell hy-
perplasia, total amount of DCs in the lung tissue, antigen-
specific IgE in serum, and IL-10 in the mLN. H. pylori 
extract affects antigen processing by DCs [12]. It is pos-
sible that the extract also induced IL-10 production by 
DCs, or that T cells that are skewed by the DCs produce 
IL-10. This is supported by the increased production of 
IL-10 after restimulation with HDM of cells of the mLN 
in mice treated with the extract. IL-10 has a central role 
in the control of asthma, and is known to inhibit many 
different cells and their functions in allergic disease, in-
cluding mast cells [19–21]. Production of IL-10 may have 
led to reduced goblet cell hyperplasia, either by an effect 
on mast cells, or by another mechanism. Another possi-
bility is that goblet cell hyperplasia is reduced as a conse-
quence of reduced IL-13 production. The role of IL-13 in 
mucus hypersecretion and induction of airway hyperre-
sponsiveness in mice has been well described and block-
ing IL-13 mainly reduces these features with less effect on 
airway inflammation [22, 23]. IL-13 is known to induce 
goblet cell hyperplasia directly in mouse epithelial cells 
[22]. The role of IL-13 in mucus hypersecretion is fur-
thermore supported by in vitro studies with cultured hu-
man airway epithelial cells, showing the ability of IL-13 to 
induce goblet cell hyperplasia [24, 25]. Two ways that 
treatment with the extract could lead to reduced IL-13 
production is that the extract affects Th2 cell skewing by 
DCs, or that the reduction in IgE leads to reduced IL-13 
release by mast cells [26]. Although we did not observe a 
reduction in production of Th2 cytokines by cells in the 
mLN after restimulation with the allergen in mice treated 
with the extract, we cannot formally exclude that IL-13 is 
reduced in BAL fluid or lung tissue. Applying the extract 
i.n. with the intention to target the epithelium directly 
proved to be less successful in inhibiting AAI than i.p. in-
jection in the more acute models [Y. van Wijck; unpubl. 
observations]. 
In clinical research it has been recognized that differ-
ent phenotypes in asthma exist, which are susceptible to 
different treatment approaches. Therefore, modelling 
asthma also needs to consider various models for differ-
ent phenotypes [6]. The most widely investigated asthma 
phenotype in such animal models is allergic, eosinophilic 
asthma. The current results show that certain character-
istics of AAI and airway remodelling can also be inhibited 
in a more chronic model of the disease by using an extract 
of H. pylori.
To conclude, treatment of AAI with an extract of H. 
pylori at the time of a rechallenge inhibited goblet cell hy-
perplasia and selected inflammatory features of the dis-
ease. Therefore, this extract or its active components 
might be meaningful as a new therapeutic option for pa-
tients with asthma.
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